<?xml version="1.0" encoding="UTF-8"?>
<p>In several clinical trials, macrolides reduced exacerbations in airways diseases, particularly asthma.
 <xref rid="rmv2163-bib-0027" ref-type="ref">
  <sup>27</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0028" ref-type="ref">
  <sup>28</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0030" ref-type="ref">
  <sup>30</sup>
 </xref> As the majority of such exacerbations are triggered by viral infections,
 <xref rid="rmv2163-bib-0031" ref-type="ref">
  <sup>31</sup>
 </xref> most commonly rhinoviruses (RV),
 <xref rid="rmv2163-bib-0032" ref-type="ref">
  <sup>32</sup>
 </xref> the effects of macrolides have been studied most extensively against RV. AZM reduces RV replication and release during in vitro infection of primary human bronchial epithelial cells (PBEC).
 <xref rid="rmv2163-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref> This finding was replicated in PBEC from patients with cystic fibrosis or healthy controls, where AZM treatment again led to a sevenfold to ninefold reduction in viral shedding, respectively.
 <xref rid="rmv2163-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref> The use of AZM alone increased viral‐induced interferons (IFNs) and interferon‐stimulated gene (ISG) mRNA expression and hence production of these gene products.
 <xref rid="rmv2163-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref> In the latter study, while viral replication was suppressed, AZM did not suppress pro‐inflammatory responses.
</p>
